TAK-242

Akaza Bioscience Ltd · Phase 2 active Small molecule

At a glance

Generic name	TAK-242
Sponsor	Akaza Bioscience Ltd
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A-TANGO Phase 2 Study (PHASE2)
TAK-242 in Patients With Acute Alcoholic Hepatitis (PHASE2)
Efficacy and Safety of Resatorvid in Patients With Sepsis-induced Cardiovascular and Respiratory Failure (PHASE3)
Efficacy & Safety of Resatorvid in Adults With Severe Sepsis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TAK-242 CI brief — competitive landscape report
TAK-242 updates RSS · CI watch RSS
Akaza Bioscience Ltd portfolio CI